Acurx Pharmaceuticals (ACXP) Cash & Equivalents (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has 7 years of Cash & Equivalents data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 99.29% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 99.29% YoY) and the FY2025 annual result came in at $7.6 million, up 103.85% from the prior year.
• Cash & Equivalents grew to $9.3 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.1 million in Q1 2022 to a low of $3.7 million in Q4 2024.
• A 5-year average of $7.6 million and a median of $7.5 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 321.68% — and 2024, when it plunged 50.41%.
• Tracing ACXP's Cash & Equivalents over 5 years: stood at $9.1 million in 2022, then decreased by 17.97% to $7.5 million in 2023, then sank by 50.41% to $3.7 million in 2024, then surged by 103.85% to $7.6 million in 2025, then increased by 22.48% to $9.3 million in 2026.
• The last three Cash & Equivalents figures came in at $9.3 million (Q1 2026), $7.6 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.